- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04198766
Studie van INBRX-106 en INBRX-106 in combinatie met pembrolizumab bij proefpersonen met lokaal gevorderde of gemetastaseerde solide tumoren (hexavalente OX40-agonist)
Een open-label, multicenter, first-in-human, dosis-escalatie, fase 1-onderzoek van INBRX-106 en INBRX-106 in combinatie met pembrolizumab bij proefpersonen met lokaal gevorderde of gemetastaseerde solide tumoren
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
- Geneesmiddel: INBRX-106 - Hexavalent OX40 agonist antibody
- Geneesmiddel: pembrolizumab 200 mg
- Geneesmiddel: pembrolizumab 400 mg
- Geneesmiddel: Carboplatin AUC-5
- Geneesmiddel: Pemetrexed 500 mg/m2
- Geneesmiddel: Cisplatin 75mg/m2
- Geneesmiddel: Carboplatin AUC-6
- Geneesmiddel: Paclitaxel 200mg/m2
- Geneesmiddel: Nab paclitaxel 100mg/m2
- Geneesmiddel: Gemcitabine (1000 mg/m2)
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
- Fase 1
Contacten en locaties
Studiecontact
- Naam: Study Director - Inhibrx Biosciences, Inc
- Telefoonnummer: 858-500-7833
- E-mail: clinicaltrials@inhibrx.com
Studie Locaties
-
-
-
Singapore, Singapore
- Voltooid
- Curie Oncology
-
Singapore, Singapore
- Voltooid
- Icon Cancer Centre Farrer Park
-
Singapore, Singapore
- Voltooid
- Icon Cancer Centre Mount Alvernia
-
-
-
-
-
Changhua, Taiwan
- Actief, niet wervend
- Changhua Christian Hospital (CCH)
-
Kaohsiung City, Taiwan
- Actief, niet wervend
- E-Da Cancer Hospital
-
Kaohsiung City, Taiwan
- Actief, niet wervend
- Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH)
-
Tainan, Taiwan
- Actief, niet wervend
- National Cheng Kung University Hospital
-
Taipei, Taiwan
- Voltooid
- Taipei Veterans General Hospital
-
-
-
-
California
-
Duarte, California, Verenigde Staten, 91010
- Actief, niet wervend
- City of Hope
-
Glendale, California, Verenigde Staten, 91204
- Werving
- Oncura Health
-
Contact:
- Elizabeth Brown
- E-mail: Elizabeth.Brown@lahomg.com
-
Hoofdonderzoeker:
- Sungwon Kyung, MD
-
La Jolla, California, Verenigde Staten, 92037
- Nog niet aan het werven
- UC San Diego Health - Moores Cancer Center
-
Hoofdonderzoeker:
- Lyudmila Bazhenova, MD
-
Los Angeles, California, Verenigde Staten, 90027
- Werving
- California Research Institute
-
Hoofdonderzoeker:
- Ghassan Al-Jazayrly, MD
-
Contact:
- Swati Shrestha
- E-mail: sw@caresinst.com
-
Los Angeles, California, Verenigde Staten, 90069
- Werving
- Valkyrie Clinical Trials
-
Hoofdonderzoeker:
- David Berz, MD
-
Contact:
- Myo Zaw
- E-mail: myo.zaw@valkyrieclinicaltrials.com
-
Los Angeles, California, Verenigde Staten, 90033
- Nog niet aan het werven
- University of Southern California Norris Comprehensive Cancer Center
-
Hoofdonderzoeker:
- Jorge Nieva, MD
-
Murrieta, California, Verenigde Staten, 92562
- Werving
- Valkyrie Clinical Trials
-
Hoofdonderzoeker:
- David Berz, MD
-
Contact:
- Isabella Gudino
- E-mail: Isabella.gudino@vctcare.com
-
Santa Rosa, California, Verenigde Staten, 95403
- Werving
- Providence Medical Foundation
-
Hoofdonderzoeker:
- Ian Anderson, MD
-
Contact:
- Clinical Research Coordinator
- Telefoonnummer: 1181 707-521-3810
- E-mail: jackson.barnard@providence.org
-
-
Colorado
-
Lakewood, Colorado, Verenigde Staten, 80228
- Nog niet aan het werven
- Valkyrie Clinical Trials - Colorado
-
Hoofdonderzoeker:
- Jason Henry, MD
-
-
Florida
-
Clermont, Florida, Verenigde Staten, 34711
- Werving
- Clermont Oncology Center
-
Hoofdonderzoeker:
- Gopal Kunta, MD
-
Contact:
- Kiran Penta
- E-mail: kiran@aorcorp.com
-
Orange City, Florida, Verenigde Staten, 32763
- Werving
- Mid Florida Hematology and Oncology Center
-
Hoofdonderzoeker:
- Santosh Nair, MD
-
Contact:
- Kiran Penta
- E-mail: kiran@aorcorp.com
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30322
- Actief, niet wervend
- Winship Cancer Institute - Emory University
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60612
- Nog niet aan het werven
- University of Illinois Cancer Center
-
Hoofdonderzoeker:
- Frank Weinberg, MD, PhD
-
Chicago, Illinois, Verenigde Staten, 60637
- Actief, niet wervend
- The University of Chicago Medical Center
-
-
Iowa
-
Iowa City, Iowa, Verenigde Staten, 52242
- Werving
- University of Iowa
-
Hoofdonderzoeker:
- Douglas Laux, MD
-
Contact:
- Jordan Harrelson
- Telefoonnummer: 319-467-5831
- E-mail: Jordan-harrelson@uiowa.edu
-
-
Kentucky
-
Louisville, Kentucky, Verenigde Staten, 40202
- Werving
- Norton Cancer Institute
-
Hoofdonderzoeker:
- John Hamm, MD
-
Contact:
- Jenn Broadway, RN
- Telefoonnummer: 19535 502-629-2500
- E-mail: Jennifer.Broadway@nortonhealthcare.org
-
-
Michigan
-
Detroit, Michigan, Verenigde Staten, 48202
- Werving
- Henry Ford Cancer Institute
-
Hoofdonderzoeker:
- Amy Weise, MD
-
Contact:
- Mahmoud Hossami
- Telefoonnummer: 313-725-7842
- E-mail: mhossam1@hfhs.org
-
Detroit, Michigan, Verenigde Staten, 48201
- Voltooid
- Barbara Ann Karmanos Cancer Institute
-
Grand Rapids, Michigan, Verenigde Staten, 49546
- Actief, niet wervend
- START Midwest
-
-
Minnesota
-
Saint Louis Park, Minnesota, Verenigde Staten, 55426
- Actief, niet wervend
- HealthPartners Cancer Research Center
-
Saint Paul, Minnesota, Verenigde Staten, 55101
- Voltooid
- HealthPartners Cancer Research Center (Regions Hospital)
-
-
Missouri
-
St Louis, Missouri, Verenigde Staten, 63110
- Nog niet aan het werven
- Washington University in St. Louis School of Medicine
-
Hoofdonderzoeker:
- Brett Herzog, MD, PhD
-
-
Montana
-
Billings, Montana, Verenigde Staten, 59102
- Voltooid
- Intermountain Health Cancer Centers of Montana
-
-
Nebraska
-
Grand Island, Nebraska, Verenigde Staten, 68803
- Nog niet aan het werven
- Nebraska Cancer Specialists - Grand Island
-
Hoofdonderzoeker:
- Ralph Hauke, MD
-
Omaha, Nebraska, Verenigde Staten, 68130
- Werving
- Nebraska Cancer Specialists
-
Hoofdonderzoeker:
- Ralph Hauke, MD
-
Contact:
- Lindsey Becker
- Telefoonnummer: 402-691-5255
- E-mail: lbecker@nebraskacancer.com
-
-
New Jersey
-
Camden, New Jersey, Verenigde Staten, 08103
- Nog niet aan het werven
- MD Anderson Cancer Center at Cooper
-
Hoofdonderzoeker:
- Polina Khrizman, MD
-
-
New York
-
The Bronx, New York, Verenigde Staten, 10467
- Actief, niet wervend
- Montefiore Medical Center
-
-
Ohio
-
Cleveland, Ohio, Verenigde Staten, 44195
- Actief, niet wervend
- Cleveland Clinic
-
-
Oregon
-
Portland, Oregon, Verenigde Staten, 97213
- Actief, niet wervend
- Providence Portland Medical Center
-
-
Pennsylvania
-
Allentown, Pennsylvania, Verenigde Staten, 18103
- Nog niet aan het werven
- Lehigh Valley Health Network
-
Hoofdonderzoeker:
- Muhammad Rizvi, MD
-
-
Tennessee
-
Knoxville, Tennessee, Verenigde Staten, 37923
- Nog niet aan het werven
- University of Tennessee Health Science Center
-
Hoofdonderzoeker:
- Sean Jordan, MD
-
Nashville, Tennessee, Verenigde Staten, 37204
- Actief, niet wervend
- Vanderbilt University School of Medicine
-
-
Texas
-
Dallas, Texas, Verenigde Staten, 75230
- Voltooid
- Sarah Cannon Research Institute at Mary Crowley
-
El Paso, Texas, Verenigde Staten, 79915
- Voltooid
- Renovatio Clinical - El Paso
-
San Antonio, Texas, Verenigde Staten, 78229
- Voltooid
- NEXT Oncology
-
The Woodlands, Texas, Verenigde Staten, 77380
- Voltooid
- Renovatio Clinical
-
Tyler, Texas, Verenigde Staten, 75701
- Werving
- The University of Texas Health Science Center at Tyler
-
Contact:
- Chaney Story
- E-mail: Chaney.Story@uttyler.edu
-
Hoofdonderzoeker:
- Erminia Massarelli, MD, PhD, MS
-
-
Virginia
-
Fairfax, Virginia, Verenigde Staten, 22031
- Voltooid
- Virginia Cancer Specialists
-
-
Wisconsin
-
Milwaukee, Wisconsin, Verenigde Staten, 53226
- Werving
- Froedtert Hospital and the Medical College of Wisconsin
-
Hoofdonderzoeker:
- Jonathan Thompson, MD
-
Contact:
- Ellen Smith
- E-mail: eksmith@mcw.edu
-
-
-
-
-
Busan, Zuid -Korea
- Nog niet aan het werven
- Inje University College of Medicine
-
Hoofdonderzoeker:
- IL-Hwan Kim, MD, PhD
-
Cheongju-si, Zuid -Korea
- Nog niet aan het werven
- Chungbuk National University Hospital
-
Hoofdonderzoeker:
- Ki-Hyeong Lee, MD
-
Gyeonggi-do, Zuid -Korea
- Werving
- The Catholic University of Korea, St. Vincent's Hospital
-
Hoofdonderzoeker:
- Byoung Yong Shim
-
Hwasun, Zuid -Korea
- Nog niet aan het werven
- Chonnam National University Hwasun Hospital
-
Hoofdonderzoeker:
- In-Jae Oh, MD, MS, PhD
-
Incheon, Zuid -Korea
- Nog niet aan het werven
- Gachon University Gil Medical Center
-
Hoofdonderzoeker:
- Eun Kyung Cho, PhD, M.S
-
Seongnam-si, Zuid -Korea
- Nog niet aan het werven
- CHA Bundang Medical Center
-
Hoofdonderzoeker:
- Yoon Beom Sang
-
Seoul, Zuid -Korea
- Werving
- Asan Medical Center
-
Contact:
- Bokyeong Jung, RN
- E-mail: bokyeong_jung@amc.seoul.kr
-
Hoofdonderzoeker:
- Dae Ho Lee, MD
-
Seoul, Zuid -Korea
- Werving
- Severance Hospital, Yonsei University Health System
-
Contact:
- Miyeon Lee
- E-mail: lee_my@yuhs.ac
-
Hoofdonderzoeker:
- Sun Mun Lim
-
Seoul, Zuid -Korea
- Werving
- The Catholic University of Korea Seoul St. Mary's Hospital,
-
Hoofdonderzoeker:
- SookHee Hong
-
Contact:
- Na Ayn
- E-mail: Ahnna331@gmail.com
-
Seoul, Zuid -Korea
- Nog niet aan het werven
- Korea University Anam Hospital
-
Hoofdonderzoeker:
- Yoon Ji Choi, MD, MS, PhD
-
Seoul, Zuid -Korea
- Nog niet aan het werven
- Hanyang University Seoul Hospital
-
Hoofdonderzoeker:
- Myung- Ju Ahn, MD, PhD, MS
-
Seoul, Zuid -Korea
- Nog niet aan het werven
- Korea University Guro Hospital
-
Hoofdonderzoeker:
- Sung Yong Lee
-
Hoofdonderzoeker:
- Sung Yong Lee, MD, MS, PhD
-
Suwon, Zuid -Korea
- Nog niet aan het werven
- Ajou University Hospital
-
Hoofdonderzoeker:
- Yong-Won Choi, MD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Select Inclusion Criteria:
- Males or females aged ≥18 years.
- Parts 1 and 3 (escalation cohorts): Subjects with locally advanced or metastatic non resectable solid tumors, whose disease has progressed despite all standard therapies or for whom no further standard or clinically acceptable therapy exists.
- Part 2 (single-agent expansion cohort): Subjects with NSCLC, melanoma, HNSCC, G/GEA, RCC, or TCC, with histologically confirmed, locally advanced or metastatic, non-resectable disease, which has progressed despite all standard therapies including CPI or for whom no standard or clinically acceptable therapy exists.
- Part 4 (expansion cohorts in combination with pembrolizumab, with or without chemotherapy): Subjects with melanoma (all types), HNSCC, G/GEA, RCC, TCC, NSCLC, or MSI-high, TMB-high, MMR-deficient tumors, with histologically confirmed, locally advanced or metastatic, non resectable disease, which is either CPI-naive (melanoma, HNSCC, NPC) or progressed despite all standard therapies including CPI (NSCLC, RCC, TCC, uveal melanoma, MSI-high, TMB-high, or MMR-deficient solid tumors) or for whom no standard or clinically acceptable therapy exists.
- For Cohort F3 (NSCLC), subjects may have progressed on no more than 2 lines of standard therapy that must include at least one PD-1/L1 regimen.
- For Cohort F4 (HNSCC and NPC), subjects may be previously treated with no more than 1 prior chemotherapy regimen in metastatic setting. Prior PD-1/L1 in curative (neo-adjuvant/adjuvant) setting is allowed only if completed >/= 6 months prior to progression to local recurrence or metastatic disease.
- For Cohort F8, subjects must have previously untreated, histologically confirmed Stage II, IIIA or IIIB (T3-4N2) NSCLC. Lymph node disease requires histologic confirmation, while T3 disease requires only radiographic documentation. Subjects need to be able to undergo planned surgery.
- All subjects with non-squamous NSCLC must have documentation of absence of tumor activating EGFR mutations and absence of ALK gene rearrangements.
- PD-L1 by IHC (22C3): Parts 1 and 3: IHC optional. Part 2: IHC result mandatory but any score allowed. Combined Positive Score (CPS) ≥ 1% (or Tumor Proportion Score ≥50% for NSCLC; for TMB-high tumors, any TPS% is allowed). Part 4: Combined Positive Score (CPS) ≥ 1% (or Tumor Proportion Score ≥50% for NSCLC; for TMB-high tumors, any TPS% is allowed). For Cohort F8, any TPS (including 0%) is acceptable.
- Adequate hematologic, coagulation, hepatic and renal function and ECOG score as defined per protocol.
Select Exclusion Criteria:
- Prior exposure to OX40 agonists. Exposure to anti-PD-1 and/or anti PD-L2 CPIs or an agent targeting other co-stimulatory T-cell receptor pathways.
- Receipt of any investigational product or any approved anticancer drug(s) or biological product(s) within 4 weeks prior to the first dose of study drug with certain exceptions.
- Hematologic malignancies (e.g., ALL, AML, MDS, CLL, CML, NHL, Hodgkin's lymphoma and multiple myeloma)
- Prior or concurrent malignancies. Exception: Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessments of INBRX-106.
- Grade ≥ 3 immune-related adverse events (irAEs) or irAE that lead to discontinuation of prior immunotherapy. Some exceptions as defined per protocol apply.
- Active autoimmune disease or documented history of autoimmune disease that required systemic steroids or other immunosuppressive medications. Certain exceptions as defined in protocol apply.
- Diagnosis of immunodeficiency or treatment with systemic immunosuppressive medications within 7 days prior to the first dose of study drug. Certain exceptions as defined in protocol apply.
- History of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection. Exceptions as defined in protocol apply.
- Active interstitial lung disease (ILD) or pneumonitis or a history of ILD or pneumonitis requiring treatment with steroids or other immunosuppressive medications.
- Clinically significant cardiac condition, including myocardial infarction, uncontrolled angina, viral myocarditis, cerebrovascular accident, or other acute uncontrolled heart disease < 3 months prior to enrollment on this trial; left ventricular ejection fraction (LVEF) < 50%; New York Heart Association (NYHA) Class III or IV congestive heart failure; or uncontrolled hypertension; or oxygen saturation <92% on room air.
- Active, hemodynamically significant pulmonary embolism within 12 weeks prior to enrollment on this trial.
- Major surgery within 4 weeks prior to enrollment on this trial.
- Anti-infectious drug treatments (i.e., antibiotics) within 4 weeks prior to the first dose of study drug.
- Prior organ allograft transplantations or allogeneic peripheral blood stem cell (PBSC) or bone marrow (BM) transplantation.
- Additional in- and exclusion criteria per protocol.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Sequentiële toewijzing
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Part 1 INBRX-106 Escalation (Not Recruiting)
INBRX-106 will be escalated in subjects with locally advanced or metastatic solid tumors. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). |
|
Experimenteel: Part 3 INBRX-106 Escalation in Combination with pembrolizumab (Not Recruiting)
INBRX-106 will be escalated, in combination with pembrolizumab, in subjects with locally advanced or metastatic solid tumors. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Andere namen:
|
|
Experimenteel: Part 2 (Cohorts C1/C2) INBRX-106 Escalation in Various Solid Tumor Types (Not Recruiting)
Subjects with melanoma (any type), head and neck squamous cell carcinoma, renal cell carcinoma, urothelial carcinoma or MSI/TMB-high tumors that are relapsed or refractory to prior checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Andere namen:
|
|
Experimenteel: Part 2 (Cohort C3) INBRX-106 Escalation in NSCLC (Not Recruiting)
Subjects with non-small cell carcinoma relapsed or refractory to prior checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 |
pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Andere namen:
|
|
Experimenteel: Part 4 (Cohort F3a) INBRX-106 Expansion in Combination with pembrolizumab in NSCLC (Not Recruiting)
Subjects with non-small cell lung cancer will be treated with alternating dosing of INBRX-106 0.3 mg/kg Q6W and 400 mg pembrolizumab IV Q6W. This is one of the randomized cohorts. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 400 mg by IV infusion given on Day 1 of alternating 21-day cycles (every 6 weeks)
Andere namen:
|
|
Experimenteel: Part 4 (Cohort F3b) INBRX-106 Expansion in Combination with pembrolizumab in NSCLC (Not Recruiting)
Subjects with non-small cell lung cancer will be given a 0.3 mg/kg priming dose of INBRX-106 in cycle 1, followed by 0.1 mg/kg INBRX-106 and 200 mg pembrolizumab IV every 3 weeks in subsequent cycles. This is one of the randomized cohorts. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Andere namen:
pembrolizumab 400 mg by IV infusion given on Day 1 of alternating 21-day cycles (every 6 weeks)
Andere namen:
|
|
Actieve vergelijker: Part 4 (Cohort F3c) Pembrolizumab Expansion Arm (Not Recruiting)
Subjects with non-small cell lung cancer will be treated with 200 mg pembrolizumab IV every 3 weeks. This is one of the randomized cohorts. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). |
|
Experimenteel: Part 4 (Cohort F3d) INBRX-106 Expansion in Combination with pembrolizumab in NSCLC (Not-Recruiting)
Subjects with non-small cell lung cancer will be treated concurrently every 6 weeks with INBRX-106 0.1 mg/kg and 200 mg pembrolizumab IV every 3 weeks. This is one of the randomized cohorts. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). |
|
Experimenteel: Part 4 (Cohort F4) INBRX-106 Expansion in Combination with pembrolizumab (Not Recruiting)
Subjects with melanoma (any type), head and neck squamous cell carcinoma (non-nasopharyngeal) OR nasopharyngeal carcinoma, MSI-high, TMB-high or MMR-deficient tumors, will be treated with INBRX-106 in combination with 200mg pembrolizumab IV every 3 weeks. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Andere namen:
|
|
Experimenteel: Part 4 (Cohort F5)INBRX-106 Expansion with pembrolizumab in MSI/TMB-high/MMRd tumors Not Recuriting
Subjects with solid tumors that have confirmed MSI-high, TMB-high or MMR-deficient states who are relapsed or refractory to checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 and 200 mg pembrolizumab IV every 3 weeks |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Andere namen:
|
|
Experimenteel: Part 4 (Cohort F6) INBRX-106 Expansion with pembrolizumab in Uveal Melanoma (Not Recruiting)
Subjects with ocular (uveal) melanoma who are relapsed or refractory to checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 and 200 mg pembrolizumab IV every 3 weeks |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Andere namen:
carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4. Cohort F8, carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycle 2-4. pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles. In Cohort F8, pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle of cycles 1-4.
Andere namen:
|
|
Experimenteel: Part 4 (Cohort F7a) INBRX-106 Expansion with pembrolizumab, pemetrexed and carboplatin in NSCLC
This Arm is no longer recruiting. Subjects with advanced/metastatic NSCLC, any PD-L1 TPS will be treated with INBRX-106 0.1mg/kg, 200mg pembrolizumab, 500mg/m2 pemetrexed and carboplatin AUC-5 IV every 3 weeks |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Andere namen:
pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles. In Cohort F8, pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle of cycles 1-4.
Andere namen:
cisplatin 75mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4 |
|
Experimenteel: Part 4 (Cohort F7b) INBRX-106 Expansion with pembrolizumab, pemetrexed and cisplatin in NSCLC
This Arm is no longer recruiting. Subjects with advanced/metastatic NSCLC, any PD-L1 TPS will be treated with INBRX-106 0.1mg/kg, 200mg pembrolizumab, 500mg/m2 pemetrexed and 75mg/m2 cisplatin IV every 3 weeks |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Andere namen:
carboplatin AUC-6 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4 paclitaxel 200mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4 Nab paclitaxel 100mg/m2 by intravenous (IV) infusion, given on Days 1, 8 and 15 of each 21-day cycle of cycles 1-4 |
|
Experimenteel: Part 4(Cohort F7c)INBRX-106 Expansion with pembrolizumab, (Nab)-paclitaxel and carboplatin in NSCLC
This Arm is no longer recruiting. Subjects with advanced/metastatic NSCLC, any PD-L1 TPS will be treated with INBRX-106 0.1mg/kg, 200mg pembrolizumab, 200mg/m2 paclitaxel and carboplatin AUC-6 IV every 3 weeks OR INBRX-106, 200mg pembrolizumab, 100mg/m2 nab-paclitaxel (dosed Days 1,8 and 15 every cycle) and carboplatin AUC-6 IV every 3 weeks. Treating physician to determine if paclitaxel or nab-paclitaxel will be given |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Andere namen:
|
|
Experimenteel: Part 4(Cohort F8)INBRX-106 with pembrolizumab, cisplatin and gemcitabine or pemetrexed in NSCLC
Subjects with resectable Stage II, IIIA or IIIB (T3-4N2) NSCLC , any PD-L1 TPS will receive neoadjuvant treatment with INBRX-106 0.1 mg/kg, 200 mg pembrolizumab, cisplatin 75 mg/m2 (dosed Day 1 only) with gemcitabine 1000 mg/m2 (dosed on Days 1 and 8) for patients with squamous cell NSCLC given every 3 weeks OR neoadjuvant treatment with INBRX-106 0.1 mg/kg, 200 mg pembrolizumab, cisplatin 75 mg/m2 with pemetrexed 500 mg/m2 for patients with non-squamous cell NSCLC given every 3 weeks. Carboplatin AUC5 (dosed on Day 1 only) can be substituted for Cisplatin for subjects who are clinically considered ineligible or unsuitable for cisplatin per the Investigator's discretion or institution SOPs. Neoadjuvant treatment will be given for up to 4 cycles followed by surgery (lobectomy, bilobectomy or pneumonectomy). After surgery, all patients will receive adjuvant treatment consisting of INBRX-106 0.1 mg/kg, 200 mg pembrolizumab given every 3 weeks for up to 13 cycles. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Andere namen:
carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4. Cohort F8, carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycle 2-4. pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles. In Cohort F8, pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle of cycles 1-4.
Andere namen:
cisplatin 75mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4 Gemcitabine 1000 mg/m2 given by intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle of cycles 1-4 |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Frequency of adverse events of INBRX-106 as single agent and in combination with pembrolizumab
Tijdsspanne: ~2 years
|
Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0 |
~2 years
|
|
Severity of adverse events of INBRX-106 as single agent and in combination with pembrolizumab
Tijdsspanne: ~2 years
|
Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0 |
~2 years
|
|
MTD and/or RP2D of INBRX-106 as single agent and in combination with pembrolizumab
Tijdsspanne: ~2 years
|
Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of INBRX-106 and INBRX-106 in combination with pembrolizumab |
~2 years
|
|
Antitumor activity of INBRX-106 in combination with pembrolizumab in expansion cohorts
Tijdsspanne: ~2 years
|
The evaluation of efficacy will be based on the subject's measurable disease using RECIST v1.1 |
~2 years
|
|
Frequency and severity of adverse events of INBRX-106 in combination with pembrolizumab and chemotherapy in adults with locally advanced or metastatic NSCLC or resectable Stage II, IIIA or IIIB (T3-4N2) NSCLC
Tijdsspanne: ~2 years
|
Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0 |
~2 years
|
|
To assess the antitumor activity of INBRX-106 in combination with pembrolizumab and platinum doublet chemotherapy as neoadjuvant/adjuvant therapy in adult subjects with NSCLC. (Cohort F8)
Tijdsspanne: ~2 years
|
Major pathological response (mPR) and pathological complete response (cPR) criteria. |
~2 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Area under the serum concentration time curve (AUC) of INBRX-106
Tijdsspanne: ~2 years
|
Area under the serum concentration time curve (AUC) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
|
Maximum observed serum concentration (Cmax) of INBRX-106
Tijdsspanne: ~2 years
|
Maximum observed serum concentration (Cmax) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
|
Trough observed serum concentration (Ctrough) of INBRX-106
Tijdsspanne: ~2 years
|
Trough observed serum concentration (Ctrough) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
|
Time to Cmax (Tmax) of INBRX-106
Tijdsspanne: ~2 years
|
Time to Cmax (Tmax) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
|
Immunogenicity of INBRX-106
Tijdsspanne: ~2 years
|
Frequency of anti-drug antibodies (ADA) against INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Anti-tumor activity of INBRX-106 as single agent and in combination with pembrolizumab with or without chemotherapy
Tijdsspanne: ~2 years
|
Tumor response will be determined by the revised Response Evaluation Criteria in Solid Tumors version 1.1 (RECISTv1.1). |
~2 years
|
|
Anti-tumor activity of INBRX-106 as single agent and in combination with pembrolizumab with or without chemotherapy
Tijdsspanne: ~2 years
|
Tumor response will be determined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1). |
~2 years
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Studie directeur: Clinical Lead, Inhibrx Biosciences, Inc
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
- Hoofd-halskanker
- Longkanker
- NSCLC
- Niet-kleincellige longkanker
- Carcinoom
- Neoplasmata
- Immunotherapie
- Pembrolizumab
- Chemotherapie
- Keytruda
- HNSCC
- Neoadjuvant
- Antineoplastische middelen
- Adjuvans
- Vaste tumoren
- Orale kanker
- Orofaryngeale kanker
- INBRX-106
- Antineoplastische middelen, immunologisch
- Hoofd- en nekneoplasmata
- Neoplasmata, glandulair en epitheel
- Neoplasmata per histologisch type
- Neoplasmata per site
- Plaveiselcelcarcinoom van hoofd en hals
- Moleculaire mechanismen van farmacologische werking
- PD-L1 positief
- Neoplasmata, plaveiselcel
- Carcinoom, plaveiselcel
- Hypofarynxkanker
- Fase 1 en Fase 2
- Fase 1 en fase 2 klinische studie
- OX40-receptoragonist
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Mondziekten
- Stomatognatische ziekten
- Urogenitale neoplasmata
- Mannelijke urogenitale ziekten
- Nier Ziekten
- Urologische ziekten
- Vrouwelijke urogenitale ziekten
- Vrouwelijke urogenitale ziekten en zwangerschapscomplicaties
- Ziekten van de luchtwegen
- Gastro-intestinale neoplasmata
- Neoplasmata van het spijsverteringsstelsel
- Ziekten van het spijsverteringsstelsel
- Gastro-intestinale aandoeningen
- Maag Ziekten
- Longziekten
- Adenocarcinoom
- Neoplasmata van de luchtwegen
- Thoracale neoplasmata
- Huidziektes
- Urologische neoplasmata
- KNO-ziekten
- Neuro-ectodermale tumoren
- Neoplasmata, kiemcellen en embryonaal
- Neoplasmata, zenuwweefsel
- Nierneoplasmata
- Carcinoom, bronchogeen
- Bronchiale neoplasmata
- Neuro-endocriene tumoren
- Faryngeale neoplasmata
- Otorinolaryngologische neoplasmata
- Faryngeale ziekten
- Nevi en melanomen
- Huidneoplasmata
- Huid- en bindweefselaandoeningen
- Plaveiselcelcarcinoom van hoofd en hals
- Neoplasmata
- Maagneoplasmata
- Carcinoom
- Longneoplasmata
- Carcinoom, plaveiselcel
- Carcinoom, niercel
- Carcinoom, niet-kleincellige long
- Hoofd- en nekneoplasmata
- Melanoma
- Neoplasmata per histologisch type
- Neoplasmata, glandulair en epitheel
- Neoplasmata, plaveiselcel
- Mond neoplasmata
- Carcinoom, overgangscel
- Orofaryngeale neoplasmata
- Neoplasmata per site
- Hypofaryngeale neoplasmata
- Aminozuren, peptiden en eiwitten
- Organische chemicaliën
- Heterocyclische verbindingen, 1-ring
- Heterocyclische verbindingen
- Heterocyclische verbindingen, 2-ring
- Heterocyclische verbindingen, gefuseerd ring
- Koolwaterstoffen
- Cycloparaffins
- Koolwaterstoffen, alicyclisch
- Koolwaterstoffen, cyclisch
- Terpenen
- Anorganische chemicaliën
- Chloorverbindingen
- Stikstofverbindingen
- Guanine
- Hypoxanthines
- Purinones
- Purines
- Glutamaten
- Aminozuren, zuur
- Aminozuren
- Aminozuren, dicarbonylisch
- Taxoids
- Cyclodecanes
- Diterpenen
- Deoxycytidine
- Cytidine
- Pyrimidine -nucleosiden
- Pyrimidines
- Gezondheidszorg economie en organisaties
- Platinumverbindingen
- Economie
- Pemetrexed
- Gemcitabine
- Paclitaxel
- Cisplatine
- pembrolizumab
- Belastingen
Andere studie-ID-nummers
- Ph 1 Ph 2 INBRX-106
- KEYNOTE A99 and MK-3475-A99 (Andere identificatie: Merck Sharp & Dohme LLC)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .